Anniina Tynjälä1,2,3, Carol Forsblom1,2,3, Valma Harjutsalo1,2,3,4, Per-Henrik Groop5,2,3,6, Daniel Gordin. 1. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland. 2. Abdominal Center Nephrology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. 3. Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. 4. National Institute for Health and Welfare, Helsinki, Finland. 5. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland per-henrik.groop@helsinki.fi. 6. Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Abstract
OBJECTIVE: Type 1 diabetes is accompanied by a significant burden of cardiovascular disease (CVD), which is poorly explained by traditional risk factors. We therefore aimed to explore whether arterial stiffness estimated by the augmentation index (AIx) predicts mortality in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: After baseline examination comprising pulse wave analysis by applanation tonometry alongside assessment of traditional cardiovascular risk factors, 906 individuals with type 1 diabetes from the Finnish Diabetic Nephropathy (FinnDiane) Study were followed up for a median of 8.2 years (interquartile range 5.7-9.7). Associations between baseline hemodynamics, including AIx, and all-cause mortality as well as a composite of cardiovascular and/or diabetes-related mortality were investigated using multivariable Cox regression models. RESULTS: The 67 individuals who died during follow-up had higher baseline AIx (median 28% [interquartile range 21-33] vs. 19% [9-27]; P < 0.001) compared with those alive. This association was independent of conventional risk factors (age, sex, BMI, HbA1c, estimated glomerular filtration rate [eGFR], and previous CVD event) in Cox regression analysis (standardized hazard ratio 1.71 [95% CI 1.10-2.65]; P = 0.017) and sustained in a subanalysis of individuals with chronic kidney disease. Similarly, higher AIx was associated with the composite secondary end point of cardiovascular and diabetes-related death (N = 53) after adjustments for sex, BMI, eGFR, previous CVD event, and height (standardized hazard ratio 2.30 [1.38-3.83]; P = 0.001). CONCLUSIONS: AIx predicts all-cause mortality as well as a composite cardiovascular and/or diabetes-related cause of death in individuals with type 1 diabetes, independent of established cardiovascular risk factors.
OBJECTIVE:Type 1 diabetes is accompanied by a significant burden of cardiovascular disease (CVD), which is poorly explained by traditional risk factors. We therefore aimed to explore whether arterial stiffness estimated by the augmentation index (AIx) predicts mortality in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: After baseline examination comprising pulse wave analysis by applanation tonometry alongside assessment of traditional cardiovascular risk factors, 906 individuals with type 1 diabetes from the Finnish Diabetic Nephropathy (FinnDiane) Study were followed up for a median of 8.2 years (interquartile range 5.7-9.7). Associations between baseline hemodynamics, including AIx, and all-cause mortality as well as a composite of cardiovascular and/or diabetes-related mortality were investigated using multivariable Cox regression models. RESULTS: The 67 individuals who died during follow-up had higher baseline AIx (median 28% [interquartile range 21-33] vs. 19% [9-27]; P < 0.001) compared with those alive. This association was independent of conventional risk factors (age, sex, BMI, HbA1c, estimated glomerular filtration rate [eGFR], and previous CVD event) in Cox regression analysis (standardized hazard ratio 1.71 [95% CI 1.10-2.65]; P = 0.017) and sustained in a subanalysis of individuals with chronic kidney disease. Similarly, higher AIx was associated with the composite secondary end point of cardiovascular and diabetes-related death (N = 53) after adjustments for sex, BMI, eGFR, previous CVD event, and height (standardized hazard ratio 2.30 [1.38-3.83]; P = 0.001). CONCLUSIONS: AIx predicts all-cause mortality as well as a composite cardiovascular and/or diabetes-related cause of death in individuals with type 1 diabetes, independent of established cardiovascular risk factors.
Authors: Bruno Lapauw; Tine De Backer; Simon Helleputte; Luc Van Bortel; Francis Verbeke; Jos Op 't Roodt; Patrick Calders Journal: Cardiovasc Diabetol Date: 2022-06-09 Impact factor: 8.949
Authors: Kaitlin M Love; William B Horton; James T Patrie; Linda A Jahn; Lee M Hartline; Eugene J Barrett Journal: BMJ Open Diabetes Res Care Date: 2022-01
Authors: Terezie Šuláková; Jiří Strnadel; Jan Pavlíček; Radka Poláková; Tomáš Seeman; Janusz Feber Journal: Front Pediatr Date: 2021-12-20 Impact factor: 3.418